MW09

MW09 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Moonwalk Biosciences for the treatment of obesity. The candidate is designed to modulate energy homeostasis, a fundamental physiological process governing the balance between energy intake and expenditure. As part of Moonwalk's metabolic disease pipeline, MW09 utilizes the company's proprietary epigenetic editing technology to target specific gene regulatory networks in adipose tissue. By leveraging siRNA-mediated gene silencing or modulation, MW09 aims to provide a durable and targeted therapeutic option for weight management, addressing the underlying biological drivers of metabolic dysfunction.